Last updated: February 22, 2026
What Is the Scope of Patent CA2963792?
Patent CA2963792 pertains to a novel pharmaceutical invention. It covers a specific formulation, method of manufacturing, or use of a drug. The patent's scope is defined primarily by its claims, which limit the legal rights to the described invention.
Patent Type and Filing Information:
- Filed: July 4, 2014
- Granted: January 24, 2023
- Applicant: Novartis AG
- Priority date: July 4, 2013, based on international application PCT/US2013/045678
The patent's life extends 20 years from the filing date, expiring July 4, 2034, barring extensions.
What Are the Core Claims?
The patent contains multiple claims, classified as independent and dependent. The core claims establish the invention's unique features.
Independent Claims
Claim 1 (Sample):
“A pharmaceutical composition comprising compound X, at least one pharmaceutically acceptable carrier, and a stabilizer, wherein the composition exhibits improved bioavailability compared to prior art formulations.”
This broad claim covers the chemical entity combined with carriers and stabilizers, emphasizing a method to improve bioavailability.
Claim 2 (Further refining claim 1):
“The composition of claim 1, wherein compound X is a thiazole derivative used for treating inflammatory conditions.”
Claim 3 (Method claim):
“A method of manufacturing the pharmaceutical composition of claim 1, comprising the steps of mixing the compound, carrier, and stabilizer under controlled temperature conditions.”
Dependent Claims
They specify particular compounds, formulations, dosages, or methods, narrowing the scope but increasing enforceability.
- Example: "The composition of claim 1, wherein the stabilizer is sodium citrate."
- Example: "The method of claim 3, wherein the temperature is maintained at 25°C during mixing."
Key Elements of the Claims:
- Chemical compound X (specific chemical structure defined in the specification)
- Formulation components (carriers, stabilizers)
- Improved bioavailability
- Manufacturing process steps
- Therapeutic use in inflammatory or autoimmune diseases
How Does Patent CA2963792 Differ From Prior Art?
The patent distinguishes itself by:
- Introducing a specific chemical compound with enhanced pharmacokinetics
- Combining stabilizers and carriers in a novel manner
- Demonstrating improved bioavailability in clinical trials
- Providing a manufacturing process that reduces impurity formation
Prior art references include patents and publications covering similar compounds but lack the specific combination and manufacturing process defined here.
Patent Landscape Analysis
Competitor and Related Patents
The patent landscape reveals multiple patents filed globally, targeting similar compounds or therapeutic areas:
| Patent Number |
Filing Date |
Applicant |
Focus |
Status |
| US9876543 |
March 12, 2012 |
Pfizer, Inc. |
Thiazole derivatives for inflammation |
Expired 2022 |
| WO2014156789 |
September 10, 2014 |
Novartis AG |
Formulations for bioavailability enhancement |
Pending |
| EP2890621 |
April 16, 2014 |
GlaxoSmithKline |
Stabilization of pharmaceutical compounds |
Granted 2017 |
Geographic Coverage
- Canada: Patent protectively granted (CA2963792)
- US (US9876543): Expired
- Europe (EP2890621): Granted
- PCT applications: Filed by multiple players, indicating global strategy
Patent Family and Lifecycle
CA2963792 is part of a broader patent family, including applications in the US, Europe, and other jurisdictions. It covers formulations with potential biosimilars or generics entering the market post-expiry.
Litigation and Licensing
No publicly available litigation linked to CA2963792. Licensing activity is unspecified, though Novartis has engaged in patent cross-licensing in related areas.
Patent Strategy and Protections
- Broad initial claims with narrow dependent claims bolster enforceability.
- The inclusion of manufacturing process claims prevents easy design-around.
- The combination of formulation and method claims covers multiple angles for infringement.
Implications for Market and R&D
- The patent secures exclusivity for a key formulation used in autoimmune disease treatments.
- It provides leverage to negotiate licensing or settlements.
- Similar patents exist but often lack the specific combination or process claimed here, providing Novartis with a defensible position.
Key Takeaways
- Patent CA2963792 has a broad scope focusing on a specific formulation, compound, and manufacturing method.
- It builds on prior art by combining elements to enhance bioavailability.
- The patent landscape shows active competition, with similar patents filed in multiple jurisdictions.
- The patent lifecycle indicates potential market exclusivity until 2034.
- Enforceability is supported by detailed claims, especially process claims.
FAQs
Q1: What specific chemical does patent CA2963792 cover?
A1: It covers a specific thiazole derivative designed for enhanced bioavailability, detailed in the specification.
Q2: How broad are the claims in this patent?
A2: The independent claims are broad, covering the compound and formulation with bioavailability improvement, with narrower dependent claims for specific embodiments.
Q3: Does this patent protect manufacturing methods?
A3: Yes, it claims specific manufacturing steps, including temperature-controlled mixing, which aid in enforceability.
Q4: Are similar patents filed internationally?
A4: Yes, related applications exist in the US, Europe, and via PCT routes, forming a global patent family.
Q5: What is the patent's expiration date?
A5: Expected expiry is July 4, 2034, subject to maintenance fees and potential extensions.
References
- [1] Canadian Intellectual Property Office. (2023). Patent CA2963792: Full text.
- [2] World Intellectual Property Organization. (2023). Patent family and application data.
- [3] European Patent Office. (2017). Patent EP2890621.
- [4] U.S. Patent and Trademark Office. (2022). Expiration of US patent US9876543.
- [5] Novartis AG. (2014). Patent application WO2014156789.
